Veoza reduces the severity of this common menopausal symptom. But at £430 a month, only the wealthy will benefit just now
After decades of neglect, menopause and the impact it has on women’s life quality is becoming a major focus of pharmaceutical research. Hence the excitement this week about a new, potentially life-changing, drug.
Part of this is the growing recognition of what a huge market it is: the NHS estimates that 13 million women are currently peri- or menopausal in the UK, which is roughly a third of the female population. The most common symptom is hot flushes, which, in addition to fatigue, mood swings and muscle weakness, can seriously impact women’s wellbeing and productivity.
Prof Devi Sridhar is chair of global public health at the University of Edinburgh
More Stories
Researchers create AI-based tool that restores age-damaged artworks in hours
Australia has ‘no alternative’ but to embrace AI and seek to be a world leader in the field, industry and science minister says
European journalists targeted with Paragon Solutions spyware, say researchers